Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05536297




Registration number
NCT05536297
Ethics application status
Date submitted
7/09/2022
Date registered
10/09/2022
Date last updated
1/05/2024

Titles & IDs
Public title
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
Scientific title
An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (GATHER2)
Secondary ID [1] 0 0
2022-002860-59
Secondary ID [2] 0 0
ISEE2009
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Geographic Atrophy 0 0
Age-Related Macular Degeneration 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - avacincaptad pegol

Experimental: avacincaptad pegol - Participants will receive avacincaptad pegol 2 mg monthly from Month 1 to Month 17.


Treatment: Drugs: avacincaptad pegol
Intravitreal Injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with Adverse Events (AEs)
Timepoint [1] 0 0
Up to 18 Months
Secondary outcome [1] 0 0
Number of participants with Anti-Drug Antibody (ADA) status
Timepoint [1] 0 0
Up to 18 Months
Secondary outcome [2] 0 0
Pharmacokinetics (PK) of avacincaptad pegol in plasma: concentration
Timepoint [2] 0 0
Up to 18 Months

Eligibility
Key inclusion criteria
- Male or female patients aged 50 years or greater diagnosed with GA inside and/or
outside of the fovea who completed Study ISEE2008 (GATHER2) through the Month 24 visit
on study treatment.

- Patient must provide new written informed consent for this OLE trial prior to
participation.

- Patient must have the ability to return for all trial visits for the duration of the
18-month trial.
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patient did not complete Study ISEE2008 (GATHER2) through the Month 24 visit on study
treatment (either avacincaptad pegol or Sham),

- Patient who had the study drug permanently withdrawn for an AE during ISEE2008 are not
eligible.

- Patient did not enroll into this OLE trial within the 90 day enrollment period.

- Patient who is pregnant or nursing

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/09/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/03/2025
Actual
Sample size
Target
Accrual to date
Final
278
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Centre for Eye Research Australia - East Melbourne
Recruitment hospital [2] 0 0
Sydney Retina Clinic - Sydney
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment postcode(s) [2] 0 0
2000 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Hawaii
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
South Dakota
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Utah
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
Argentina
State/province [22] 0 0
Sante Fe
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Mendoza
Country [25] 0 0
Argentina
State/province [25] 0 0
Santa Fe
Country [26] 0 0
Austria
State/province [26] 0 0
Styria
Country [27] 0 0
Austria
State/province [27] 0 0
Tyrol
Country [28] 0 0
Austria
State/province [28] 0 0
Vienna
Country [29] 0 0
Belgium
State/province [29] 0 0
Brussels
Country [30] 0 0
Brazil
State/province [30] 0 0
Belo Horizonte
Country [31] 0 0
Brazil
State/province [31] 0 0
São Paulo
Country [32] 0 0
Canada
State/province [32] 0 0
Alberta
Country [33] 0 0
Canada
State/province [33] 0 0
Ontario
Country [34] 0 0
Colombia
State/province [34] 0 0
Bogota
Country [35] 0 0
Colombia
State/province [35] 0 0
Medellin
Country [36] 0 0
Croatia
State/province [36] 0 0
Osijek
Country [37] 0 0
Czechia
State/province [37] 0 0
Smíchov
Country [38] 0 0
France
State/province [38] 0 0
Bordeaux
Country [39] 0 0
France
State/province [39] 0 0
Créteil
Country [40] 0 0
France
State/province [40] 0 0
Ecully
Country [41] 0 0
France
State/province [41] 0 0
Lyon
Country [42] 0 0
France
State/province [42] 0 0
Marseille
Country [43] 0 0
France
State/province [43] 0 0
Paris
Country [44] 0 0
France
State/province [44] 0 0
Saint Cyr sur Loire
Country [45] 0 0
Germany
State/province [45] 0 0
Hamburg
Country [46] 0 0
Germany
State/province [46] 0 0
Hannover
Country [47] 0 0
Germany
State/province [47] 0 0
München
Country [48] 0 0
Germany
State/province [48] 0 0
Münster
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Israel
State/province [50] 0 0
Ashkelon
Country [51] 0 0
Israel
State/province [51] 0 0
Haifa
Country [52] 0 0
Israel
State/province [52] 0 0
Rehovot
Country [53] 0 0
Israel
State/province [53] 0 0
Tzrifin
Country [54] 0 0
Italy
State/province [54] 0 0
Bologna
Country [55] 0 0
Italy
State/province [55] 0 0
Chieti
Country [56] 0 0
Italy
State/province [56] 0 0
Ferrara
Country [57] 0 0
Italy
State/province [57] 0 0
Milano
Country [58] 0 0
Italy
State/province [58] 0 0
Napoli
Country [59] 0 0
Italy
State/province [59] 0 0
Roma
Country [60] 0 0
Italy
State/province [60] 0 0
Torrette Di Ancona
Country [61] 0 0
Latvia
State/province [61] 0 0
Riga
Country [62] 0 0
Spain
State/province [62] 0 0
Madrid
Country [63] 0 0
Spain
State/province [63] 0 0
Barcelona
Country [64] 0 0
Spain
State/province [64] 0 0
Bilbao
Country [65] 0 0
Spain
State/province [65] 0 0
Cordoba
Country [66] 0 0
Spain
State/province [66] 0 0
Sant Cugat del Valles
Country [67] 0 0
Spain
State/province [67] 0 0
Santiago de Compostela
Country [68] 0 0
Spain
State/province [68] 0 0
Valencia
Country [69] 0 0
Spain
State/province [69] 0 0
Valladolid
Country [70] 0 0
Spain
State/province [70] 0 0
Zaragoza

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Astellas Pharma Global Development, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal
administration for patients with geographic atrophy (GA) who completed Study ISEE2008
(GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).
Trial website
https://clinicaltrials.gov/ct2/show/NCT05536297
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Astellas Pharma Global Development, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries